Abstract
No public abstract is available from the verified source records.
Drew A. Wells, Lisa Hayes, Katharyn Walker
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers’ Task Group on Psychedelics and Related Compounds
10.1016/j.eclinm.2025.103517 · 2025
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
10.1016/j.neuropharm.2017.12.041 · 2018
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
10.1177/0269881114548296 · 2014
Drug–drug interactions involving classic psychedelics: a systematic review
10.1177/02698811231211219 · 2024
Trial of psilocybin versus escitalopram for depression
10.1056/nejmoa2032994 · 2021
Rise of the mushrooms: effects of psilocybin reforms on psychedelic usage patterns
10.1177/07439156251360774 · 2026
Psychedelic drug legislative reform and legalization in the US
10.1001/jamapsychiatry.2022.4101 · 2023
Psilocybin trends in states that decriminalized use
10.1001/jama.2026.1952 · 2026
Psilocybin dispensaries and online health claims in Canada
10.1001/jamanetworkopen.2025.2853 · 2025
openalex
Confidence 95%
datacite
Confidence 0%
Microdosing psychedelics: current evidence from controlled studies
2024
A case report of psilocybin-induced psychosis in a predisposed patient
10.9758/cpn.24.1180 · 2024
The many faces of psilocybin-related psychosis: a case series
2025
Wild-mushroom intoxication as a cause of rhabdomyolysis
10.1056/nejmoa010581 · 2001
A method for estimating the probability of adverse drug reactions
10.1038/clpt.1981.154 · 1981
No additional external references are available.